Construction and validation of a novel prognostic model for intrahepatic cholangiocarcinoma based on a combined scoring system of systemic immune-inflammation index and albumin-bilirubin: a multicenter study. This evidence concerns the gene ALB and intrahepatic cholangiocarcinoma.